SCHEMBL2495119

SCHEMBL2495119

Cc1c(C(=O)O)ccc(C=O)c1OC(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.38
L3MBTL1 Q9Y468 4/20 0.38
POLB P06746 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MAPT P10636 3/20 0.34
HPGD P15428 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TEAD4 Q15561 1/20 0.34
TAS2R14 Q9NYV8 1/20 0.33
NSD2 O96028 1/20 0.32
PKM P14618 1/20 0.32
APEX1 P27695 1/20 0.32
CASP3 P42574 1/20 0.32
RECQL P46063 1/20 0.32
CASP6 P55212 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31309967 0.81 CA1 (0.46) ALDH1A1L3MBTL1POLBTDP1KDM4E
SCHEMBL2531130 0.81 ALDH1A1 (0.40) ALDH1A1TDP1KDM4ERAB9AMAPT
SCHEMBL17599653 0.75 ALDH1A1 (0.44) ALDH1A1L3MBTL1POLBTDP1KDM4E
SCHEMBL1356924 0.75 ALDH1A1 (0.34) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL12760674 0.75 ALDH1A1 (0.46) ALDH1A1L3MBTL1POLBTDP1KDM4E
SCHEMBL20594317 0.70 GABRP (0.46) ALDH1A1L3MBTL1POLBTDP1KDM4E
SCHEMBL27667878 0.70 ALDH1A1 (0.39) ALDH1A1TDP1KDM4ENPC1RAB9A
SCHEMBL18124516 0.69 TSHR (0.48) ALDH1A1L3MBTL1TDP1MEN1KMT2A
SCHEMBL28167810 0.69 CA1 (0.40) ALDH1A1L3MBTL1TDP1KDM4EMAPT
SCHEMBL8384594 0.68 POLB (0.41) ALDH1A1L3MBTL1POLBTDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813613-B1 NOVEL FUSED IMIDAZOLE DERIVATIVE MSD KK (JP) 2012-12-19 EP disclosed
US-8030327-B2 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle MDS K.K. (JP) 2011-10-04 US disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 US disclosed
EP-1813613-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103136-A1 Novel Fused Imidazole Derivative HRH4, H1-4, H1-3 ALDH1A1 1939/4885L3MBTL1 2047/4885POLB 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.